Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
PTC:VS-TC
Phase 1 other active
Quick answer
Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies. is a Phase 1 program (other) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Istituto Gentili S.r.l.
- Indication
- Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.
- Phase
- Phase 1
- Modality
- other
- Status
- active